See more : Compass Digital Acquisition Corp. (CDAQW) Income Statement Analysis – Financial Results
Complete financial analysis of Zymergen Inc. (ZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymergen Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Angel Oak Mortgage, Inc. (AOMR) Income Statement Analysis – Financial Results
- TKB Critical Technologies 1 (USCT) Income Statement Analysis – Financial Results
- Summit Bank Group, Inc. (SBKO) Income Statement Analysis – Financial Results
- CompuGroup Medical SE & Co. KGaA (CMPUY) Income Statement Analysis – Financial Results
- Shanghai Dazhong Public Utilities(Group) Co.,Ltd. (600635.SS) Income Statement Analysis – Financial Results
Zymergen Inc. (ZY)
About Zymergen Inc.
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 16.74M | 13.28M | 15.42M |
| Cost of Revenue | 69.72M | 84.82M | 102.64M |
| Gross Profit | -52.98M | -71.53M | -87.22M |
| Gross Profit Ratio | -316.42% | -538.50% | -565.67% |
| Research & Development | 159.12M | 90.85M | 50.72M |
| General & Administrative | 83.01M | 60.08M | 61.25M |
| Selling & Marketing | 23.65M | 18.63M | 24.14M |
| SG&A | 106.66M | 78.70M | 85.39M |
| Other Expenses | 175.51M | 0.00 | 0.00 |
| Operating Expenses | 265.78M | 169.56M | 136.10M |
| Cost & Expenses | 335.50M | 254.37M | 238.74M |
| Interest Income | 64.00K | 492.00K | 4.92M |
| Interest Expense | 14.71M | 10.96M | 2.94M |
| Depreciation & Amortization | 20.70M | 18.71M | 15.20M |
| EBITDA | -326.33M | -232.58M | -218.65M |
| EBITDA Ratio | -1,949.08% | -1,750.80% | -1,418.08% |
| Operating Income | -347.03M | -241.09M | -237.11M |
| Operating Income Ratio | -2,072.68% | -1,814.88% | -1,537.80% |
| Total Other Income/Expenses | -14.71M | -21.15M | 318.00K |
| Income Before Tax | -361.73M | -262.24M | -236.80M |
| Income Before Tax Ratio | -2,160.51% | -1,974.13% | -1,535.74% |
| Income Tax Expense | 51.00K | -49.00K | 8.00K |
| Net Income | -361.79M | -262.19M | -236.80M |
| Net Income Ratio | -2,160.81% | -1,973.76% | -1,535.79% |
| EPS | -4.87 | -2.68 | -2.42 |
| EPS Diluted | -4.87 | -2.68 | -2.42 |
| Weighted Avg Shares Out | 74.31M | 97.94M | 97.94M |
| Weighted Avg Shares Out (Dil) | 74.31M | 97.94M | 97.94M |
Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.
Gingko Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.
ZY Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Zymergen Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Zymergen Inc. (NASDAQ: ZY) to Ginkgo Bioworks for 0.9179 Ginkgo shares for each Zymergen share is fair to Zymergen shareholders. Halper Sadeh encourages Zymergen...
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's...
Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug discovery platform Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug...
Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications
EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the...
Good Penny Stocks to Buy Now? 3 to Watch in June
Check these penny stocks out for your watchlist right now The post Good Penny Stocks to Buy Now? 3 to Watch in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant's next-generation platform to develop breakthrough...
Zymergen: A Humbled Company With A Business On The Ropes
The stock for Zymergen Inc. has been in freefall since an initial recovery attempt following last year's disaster. The company will run out of cash in 2023 and prospects for viability remain murky.
Zymergen, Inc. (ZY) CEO Jay Flatley on Q1 2022 Results - Earnings Call Transcript
Zymergen, Inc. (NASDAQ:ZY ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Carrie Mendivil - IR Jay Flatley - Acting CEO Ena Singh - CFO Conference Call Participants Matt Sykes - Goldman Sachs Steven Mah...
Source: https://incomestatements.info
Category: Stock Reports